Brokerages Set OrthoPediatrics Corp. (NASDAQ:KIDS) PT at $23.89

Shares of OrthoPediatrics Corp. (NASDAQ:KIDS) have received an average rating of “Moderate Buy” from the eleven research firms that are presently covering the firm, MarketBeat.com reports. One research analyst has rated the stock with a sell recommendation, one has issued a hold recommendation, eight have assigned a buy recommendation and one has assigned a strong buy recommendation to the company. The average 1-year price objective among brokerages that have covered the stock in the last year is $23.8889.

Several brokerages recently weighed in on KIDS. Canaccord Genuity Group initiated coverage on shares of OrthoPediatrics in a research note on Wednesday, December 10th. They set a “buy” rating and a $24.00 target price on the stock. Needham & Company LLC cut their price objective on OrthoPediatrics from $42.00 to $26.00 and set a “buy” rating on the stock in a research report on Wednesday, October 29th. Wall Street Zen upgraded OrthoPediatrics from a “sell” rating to a “hold” rating in a report on Saturday, January 17th. TD Cowen raised OrthoPediatrics to a “strong-buy” rating in a research note on Tuesday, January 27th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of OrthoPediatrics in a research report on Thursday, January 22nd.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in shares of OrthoPediatrics by 6.9% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 9,995 shares of the company’s stock valued at $246,000 after purchasing an additional 645 shares during the last quarter. Russell Investments Group Ltd. increased its holdings in OrthoPediatrics by 433.1% in the third quarter. Russell Investments Group Ltd. now owns 1,402 shares of the company’s stock valued at $26,000 after buying an additional 1,139 shares during the last quarter. BNP Paribas Financial Markets raised its stake in OrthoPediatrics by 60.2% in the third quarter. BNP Paribas Financial Markets now owns 3,288 shares of the company’s stock valued at $61,000 after buying an additional 1,235 shares in the last quarter. Connor Clark & Lunn Investment Management Ltd. lifted its holdings in OrthoPediatrics by 12.4% during the 2nd quarter. Connor Clark & Lunn Investment Management Ltd. now owns 15,901 shares of the company’s stock worth $342,000 after buying an additional 1,753 shares during the last quarter. Finally, Northwestern Mutual Wealth Management Co. boosted its position in shares of OrthoPediatrics by 5,226.5% during the 4th quarter. Northwestern Mutual Wealth Management Co. now owns 2,610 shares of the company’s stock worth $46,000 after acquiring an additional 2,561 shares in the last quarter. Institutional investors and hedge funds own 69.05% of the company’s stock.

OrthoPediatrics Stock Performance

Shares of OrthoPediatrics stock opened at $16.89 on Friday. The company has a debt-to-equity ratio of 0.28, a current ratio of 7.40 and a quick ratio of 3.52. The stock has a market capitalization of $423.60 million, a price-to-earnings ratio of -8.66 and a beta of 1.12. The business has a 50-day moving average of $17.80 and a 200 day moving average of $18.36. OrthoPediatrics has a 12 month low of $15.28 and a 12 month high of $26.40.

About OrthoPediatrics

OrthoPediatrics Corp., founded in 2007 and headquartered in Warsaw, Indiana, is a medical device company dedicated exclusively to providing orthopedic solutions for children. The company focuses on developing, manufacturing and marketing a broad portfolio of implants and instruments designed to address a wide range of pediatric conditions, including trauma, deformity correction, spine disorders and sports injuries.

The company’s product lines include locking plates and screws for upper and lower extremity reconstruction, intramedullary nails for femur and tibia stabilization, and specialized systems such as the MAGEC Magnetic Growth Rod for treatment of early-onset scoliosis.